Surprise German Decision Boosts Jardiance Pricing Potential
Executive Summary
Boehringer Ingelheim/Lilly’s Jardiance has become one of the first of the newer antidiabetic agents to be viewed favorably by Germany's health technology assessment body, the G-BA. The surprise ruling paves the way for favorable pricing discussions.
You may also be interested in...
Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto
The latest drug development news and highlights from our FDA Performance Tracker.
Cardiovascular Data To Propel Jardiance Ahead Of Rivals
The sodium-glucose cotransporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/ Eli Lilly) is expected to experience a significant increase in uptake in the type 2 diabetes market after the presentation of its much-anticipated cardiovascular (CV) outcomes data at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden.
Sensing No Room For Price Compromise, Janssen Pulls Invokana From Germany
After a disappointing assessment from Germany’s two reimbursement bodies, Janssen has opted to withdraw it diabetes drug, believing it cannot secure a competitive price.